SecBot SecBot
SECBOTREPLAY Home › Report › PHAR

PHAR · The U.K

Pharming Group N.V. · 6-K filed Nov 6, 2026 at 06:09 ET

At the news

BULLISHIMPACT 5/10

6-K filed Nov 6, 2026 at 06:09 ET

The U.K. MHRA approved an extension of Joenja (leniolisib) to include children aged 4-11 years with APDS, expanding the existing U.K. indication previously limited to adults and adolescents 12+. The drug is expected to become available in February 2027. This is a regulatory label expansion for an already-approved product, not a new drug approval or periodic financial results.

  • MHRA approved Joenja (leniolisib) for children aged 4-11 years with APDS weighing at least 27 kg
  • Expands existing U.K. indication previously for adults and adolescents 12+
  • Expected to become available to patients in February 2027
  • Approval supported by pediatric clinical program data under MHRA-agreed Pediatric Investigation Plan

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access